ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2016
Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Obesity facts · 2024Guideline
- Platelet subpopulations and contribution to hemostasis.Blood science (Baltimore, Md.) · 2026Review
- Multichamber Myocardial Strain for Cardiovascular Risk Stratification in Liver Transplant Recipients Using Interpretable Machine Learning.JACC. Advances · 2026Article
- Impact of Glucagon-like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors on Post-liver Transplant New-onset Major Adverse Cardiovascular Events, Graft Failure, Renal Outcome, and Mortality.Transplantation direct · 2026Article
- Steatotic liver disease and liver transplantation: Candidate selection and post-transplant management.JHEP reports : innovation in hepatology · 2026Review
- Dynamic kinetics of graft-derived cell-free DNA and personalized tacrolimus target ranges for acute rejection monitoring in pediatric liver transplantation.Frontiers in pharmacology · 2026Article
- Major adverse cardiovascular events after liver transplantation: a population cohort analysis of English transplant centres.EClinicalMedicine · 2026Article
- Risk factors associated with adverse cardiovascular events during orthotopic liver transplantation and the early post-transplant period.Croatian medical journal · 2025Article
- Diagnostic accuracy and cost-effectiveness of the CAR-OLT score in predicting cardiac risk for liver transplantation.World journal of transplantation · 2025Article
- Advances and challenges in the application of donor-derived cell-free DNA for diagnosis and treatment in liver transplantation: a narrative review.BMC surgery · 2025Review
- Hemodynamic Monitoring During Liver Transplantation for Patients on Perioperative Extracorporeal Membrane Oxygenation (ECMO) Support: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Donor-derived cell-free DNA and miRNA monitoring for the early prediction and diagnosis of liver allograft rejection and patient outcomes.Frontiers in immunology · 2025Observational
- Frailty after Liver Transplantation: A Complex Unexplored Issue.Journal of clinical medicine · 2024Review
- Deep Learning-Based Prediction Modeling of Major Adverse Cardiovascular Events After Liver Transplantation.Mayo Clinic proceedings. Digital health · 2024Article
- Serious Safety Signals and Prediction Features Following COVID-19 mRNA Vaccines Using the Vaccine Adverse Event Reporting System.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Predicting major adverse cardiovascular events after orthotopic liver transplantation using a supervised machine learning model: A cohort study.World journal of hepatology · 2024Article
- Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant.Cancers · 2023Review
- Evaluation of recipients with significant comorbidity - Patients with cardiovascular disease.Journal of hepatology · 2023Review
- Characteristics of stroke after liver and kidney transplantation.Frontiers in neurology · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Assessment of major adverse cardiovascular events (MACE) after liver transplantation (LT) has been limited by the lack of a multicenter study with detailed clinical information. An integrated database linking information from the University HealthSystem Consortium and the Organ Procurement and Transplant Network was analyzed using multivariate Poisson regression to assess factors associated with 30- and 90-day MACE after LT (February 2002 to December 2012). MACE was defined as myocardial infarction (MI), heart failure (HF), atrial fibrillation (AF), cardiac arrest, pulmonary embolism, and/or stroke. Of 32 810 recipients, MACE hospitalizations occurred in 8% and 11% of patients at 30 and 90 days, respectively. Recipients with MACE were older and more likely to have a history of nonalcoholic steatohepatitis (NASH), alcoholic cirrhosis, MI, HF, stroke, AF and pulmonary and chronic renal disease than those without MACE. In multivariable analysis, age >65 years (incidence rate ratio [IRR] 2.8, 95% confidence interval [95% CI] 1.8-4.4), alcoholic cirrhosis (IRR 1.6, 95% CI 1.2-2.2), NASH (IRR 1.6, 95% CI 1.1-2.4), pre-LT creatinine (IRR 1.1, 95% CI 1.04-1.2), baseline AF (IRR 6.9, 95% CI 5.0-9.6) and stroke (IRR 6.3, 95% CI 1.6-25.4) were independently associated with MACE. MACE was associated with lower 1-year survival after LT (79% vs. 88%, p < 0.0001). In a national database, MACE occurred in 11% of LT recipients and had a negative impact on survival. Pre-LT AF and stroke substantially increase the risk of MACE, highlighting potentially high-risk LT candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.